1130 related articles for article (PubMed ID: 29972757)
21. Inotersen: First Global Approval.
Keam SJ
Drugs; 2018 Sep; 78(13):1371-1376. PubMed ID: 30120737
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
[TBL] [Abstract][Full Text] [Related]
23. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
[TBL] [Abstract][Full Text] [Related]
24. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
Mahfouz M; Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784
[TBL] [Abstract][Full Text] [Related]
25. The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.
Yarlas A; Lovley A; Brown D; Vera-Llonch M; Khella S; Karam C
BMC Neurol; 2023 Mar; 23(1):108. PubMed ID: 36932361
[TBL] [Abstract][Full Text] [Related]
26. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
Conceição I
Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
[TBL] [Abstract][Full Text] [Related]
27. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
[TBL] [Abstract][Full Text] [Related]
28. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
[TBL] [Abstract][Full Text] [Related]
29. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
30. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
[No Abstract] [Full Text] [Related]
31. [Gene therapy options for hereditary transthyretin-related amyloidosis].
Schilling M
Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity Assessment of Inotersen, a 2'-
Yu RZ; Wang Y; Norris DA; Kim TW; Narayanan P; Geary RS; Monia BP; Henry SP
Nucleic Acid Ther; 2020 Oct; 30(5):265-275. PubMed ID: 32833564
[TBL] [Abstract][Full Text] [Related]
33. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
[TBL] [Abstract][Full Text] [Related]
34. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
[TBL] [Abstract][Full Text] [Related]
35. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
36. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
37. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
Mathew V; Wang AK
Drug Des Devel Ther; 2019; 13():1515-1525. PubMed ID: 31118583
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
[TBL] [Abstract][Full Text] [Related]
39. Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis.
Gales L
Pharmaceuticals (Basel); 2019 May; 12(2):. PubMed ID: 31117178
[TBL] [Abstract][Full Text] [Related]
40. A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
Severi D; Palumbo G; Spina E; Iovino A; Nolano M; Manganelli F; Tozza S
Neurol Sci; 2023 Apr; 44(4):1419-1422. PubMed ID: 36576645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
